HIV vs. AIDS: What You Should Know About These Commonly Confused Terms

Updated Dec 3, 2024 | 11:43 AM IST

SummaryWorld AIDS Day, observed on December 1st, raises awareness about HIV/AIDS, promotes education, supports those affected, and advocates for global action to eliminate the pandemic, emphasizing early detection, treatment, and prevention.
World Aids Day

World Aids Day

The global challenge of HIV/AIDS remains one of the most pressing public health issues today. According to the latest data from UNAIDS, around 38.4 million people worldwide are living with HIV/AIDS, underlining the need for not only medical intervention but also comprehensive awareness, education, and social change. Despite the significant strides made in treatment and prevention, the confusion surrounding the relationship between HIV and AIDS still persists.

Young people have become influential advocates in the fight against HIV/AIDS. Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities. These young activists utilize digital platforms and peer-to-peer education to dispel myths, promote safe practices, and foster supportive environments for those affected by HIV/AIDS.

Dr Gowri Kulkarni, an expert in Internal Medicine, explains that while the terms HIV and AIDS are often used interchangeably, they are distinctly different. "HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, whereas AIDS (Acquired Immunodeficiency Syndrome) is a condition that occurs when HIV severely damages the immune system," she clarifies. To understand the implications of these differences, it's important to explore the fundamental distinctions between the two.

1. HIV is a Virus; AIDS is a Syndrome

HIV is the virus responsible for attacking the body’s immune system, specifically targeting CD4 cells, which are crucial for the body’s defense against infections. As HIV progresses, it destroys these cells, weakening the immune system over time. If left untreated, this continuous damage can lead to AIDS.

AIDS, on the other hand, is a syndrome, not a virus. Dr Kulkarni further elaborates that AIDS is a collection of symptoms and illnesses that emerge when the immune system is severely compromised due to prolonged HIV infection. It represents the most advanced stage of HIV, and is characterized by very low CD4 counts or the onset of opportunistic infections like tuberculosis, pneumonia, or certain cancers.

2. Not Everyone with HIV Develops AIDS

A key distinction to remember is that not everyone with HIV will progress to AIDS. Thanks to advancements in medicine, particularly antiretroviral therapy (ART), individuals living with HIV can manage the virus and maintain a healthy immune system for many years, or even decades, without ever developing AIDS. ART works by suppressing the virus to undetectable levels, effectively preventing the damage HIV would otherwise cause to the immune system.

Without treatment, however, HIV progresses through three stages:

- Acute HIV Infection: This stage occurs shortly after transmission and may include symptoms like fever, fatigue, and swollen lymph nodes.

- Chronic HIV Infection: Often asymptomatic or mildly symptomatic, the virus continues to damage the immune system but at a slower rate.

- AIDS: This is the final stage, marked by severe immune damage and the presence of infections that take advantage of the compromised immune defenses.

3. HIV is Transmissible; AIDS is Not

Another key distinction between HIV and AIDS is the way in which they are transmitted. HIV is highly contagious and can be transmitted through the exchange of bodily fluids such as blood, semen, vaginal fluids, and breast milk. It is primarily spread through unprotected sexual contact, sharing needles, or from mother to child during childbirth or breastfeeding.

AIDS, however, is not transmissible. It is not a disease that can be passed from one person to another. Rather, AIDS is the result of untreated, advanced HIV infection and is a direct consequence of the virus’s damage to the immune system.

4. Diagnosis Methods Differ

HIV and AIDS are diagnosed through different methods. HIV is diagnosed through blood tests or oral swabs that detect the presence of the virus or antibodies produced by the immune system in response to the virus. Early detection of HIV is crucial, as it allows for timely intervention and treatment, which can prevent the virus from progressing to AIDS.

AIDS, on the other hand, is diagnosed using more specific criteria. Dr Kulkarni notes that the diagnosis of AIDS is made when the individual’s CD4 cell count falls below 200 cells/mm³, or when opportunistic infections or certain cancers (such as Kaposi's sarcoma or lymphoma) are detected. Diagnosing AIDS involves a more thorough assessment of the individual’s immune function and overall health, as opposed to just the detection of HIV.

5. Treatment Goals Are Different

The treatment goals for HIV and AIDS differ significantly, although both involve antiretroviral therapy (ART). For HIV, the primary treatment goal is to suppress the virus to undetectable levels, thus maintaining a strong immune system and preventing further transmission of the virus. People living with HIV can often live long, healthy lives if they adhere to ART.

For individuals diagnosed with AIDS, the treatment plan becomes more complex. While ART remains an essential part of managing the virus, treatment for AIDS also focuses on addressing the opportunistic infections and secondary health complications associated with severe immune suppression. The goal of treatment for AIDS is not only to manage the HIV virus but also to improve the quality of life and extend survival by treating these secondary health issues.

Role of Community Engagement in Combatting HIV/AIDS

While the medical community has made great strides in managing HIV, the battle to curb its transmission is also a social and cultural issue. Dr Daman Ahuja, a public health expert, highlights that HIV/AIDS awareness and education are vital to reducing transmission rates and supporting those affected by the virus. "Young people, especially, have become key advocates in the fight against HIV/AIDS," says Dr Ahuja. "Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities."

Additionally, grassroots activism plays a significant role in raising awareness and addressing stigma. As the World Health Organization reports, community-based interventions have been proven to increase HIV testing rates and improve treatment adherence, which are crucial in the fight against the pandemic.

The ultimate goal of organizations like UNAIDS is to eliminate the HIV/AIDS pandemic by 2030. Achieving this requires global collaboration, from medical treatment advancements to public health strategies, education, and advocacy. Dr Kulkarni’s insight underscores the importance of early detection, treatment adherence, and community support in the fight against HIV/AIDS.

Dr Gowri Kulkarni is Head of Medical Operations at MediBuddy and Dr Daman Ahuja, a public health expert and has been associated with Red Ribbon Express Project of NACO between 2007-12.

End of Article

6-in-1 Vaccine Could Make India's Childhood Immunization Program More Efficient, Cut Costs: Health Ministry Study

Updated Aug 4, 2026 | 03:00 PM IST

SummaryThe study showed that although the hexavalent vaccine carries a higher upfront procurement cost, it also generates important efficiencies by reducing injections, easing pressure on frontline health workers, lowering cold-chain requirements and saving caregivers' time.
6-in-1 Vaccine Could Make India's Childhood Immunization Program More Efficient, Cut Costs: Health Ministry Study

Credit: iStock

A six-in-one (hexavalent) vaccine could make India's Universal Immunization Program more efficient, convenient for families, and cost-effective if it becomes widely available at an affordable price, according to a study led by the Ministry of Health and Family Welfare.

The study found that while the hexavalent vaccine has higher upfront procurement costs, it could reduce the number of injections, improve operational efficiency, lower healthcare workload, and save time for caregivers.

What Is the 6-in-1 Vaccine?

The hexavalent vaccine protects children against six diseases with a single injection:

  • Diphtheria
  • Tetanus
  • Pertussis (whooping cough)
  • Hepatitis B
  • Hemophilus influenzae type b (Hib)
  • Polio

Combining multiple vaccines into one shot reduces the number of injections infants receive during routine immunization visits.

Key Findings

Also read: India Records 20,138 Organ Transplants In 2025; Deceased Donor Transplants Reach 3,526

Researchers found that the vaccine's price is the biggest factor determining the overall cost of introducing it into India's immunization program.

The study estimated that:

  • A 50% reduction in the vaccine price would allow operational savings to outweigh the additional vaccine procurement costs under the primary immunization schedule.
  • Lower vaccine prices could also make broader implementation, including booster doses, economically beneficial.
Dr. Susmita Chatterjee, Program Head – Health Economics at The George Institute, said combination vaccines have long been recognized for simplifying immunization programs while improving convenience for families and health systems.

The findings were published in the peer-reviewed journal Human Vaccines & Immunotherapeutics.

Potential Benefits of the 6-in-1 Vaccine

According to the study, introducing the hexavalent vaccine could:

  • Reduce the number of injections for infants.
  • Make immunization visits more convenient for children and caregivers.
  • Lower cold-chain storage requirements
  • Reduce the use of syringes and other vaccination supplies.
  • Save time for Auxiliary Nurse Midwives (ANMs) during vaccine administration and record-keeping
  • Reduce the workload of cold-chain handlers and vaccine managers.
  • Save time for parents and caregivers during vaccination visits.

India's Current Immunization Program

Read More: India's National Hepatitis Program Screens Over 210.6 Million, Treats 612,000 Patients

India runs one of the world's largest immunization programs, vaccinating nearly 26 million babies every year.

The program protects children against 12 vaccine-preventable diseases, including:

  • Diphtheria
  • Pertussis
  • Tetanus
  • Polio
  • Measles
  • Rubella
  • Tuberculosis
  • Hepatitis B
  • Hib-related meningitis and pneumonia
  • Rotavirus diarrhea
  • Pneumococcal pneumonia
  • Japanese encephalitis (in endemic districts)

What the Study Evaluated

A team of researchers, including from The George Institute for Global Health India, The Gates Foundation, and Gavi, The Vaccine Alliance, assessed two implementation scenarios:

  • Replacing the current pentavalent vaccine and fractional inactivated polio vaccine (fIPV) with the hexavalent vaccine during the primary immunization schedule.
  • Replacing both the primary schedule and the DTP booster dose with the hexavalent vaccine.

The analysis considered costs from both government and household perspectives, including:

  • Vaccine procurement
  • Syringes and vaccination supplies
  • Cold-chain logistics
  • Healthcare worker time
  • Caregiver time

The researchers noted that replacing the current pentavalent, fIPV and DTP booster vaccines with the hexavalent vaccine would initially increase vaccine procurement costs. However, these would be partially offset by savings from:

  • Lower vaccine delivery costs
  • Reduced syringe use
  • Lower cold-chain requirements
  • Time savings for healthcare workers involved in procurement, storage and vaccine administration

The team added that based on previous vaccine procurement trends, a 50% reduction in the hexavalent vaccine price would make the switch economically favorable under the primary immunization schedule. Further price reductions could also generate cost savings for the booster-dose scenario.

"Our study demonstrates that although the hexavalent vaccine carries a higher upfront procurement cost, it also generates important efficiencies by reducing injections, easing pressure on frontline health workers, lowering cold-chain requirements and saving caregivers' time. These findings provide important economic evidence that can inform future policy discussions on strengthening India's immunization program," Dr. Susmita said.

End of Article

Can GLP-1 Drugs Like Ozempic Treat Alcohol Use Disorder? US Launches Veterans Trial

Updated Aug 3, 2026 | 06:00 PM IST

Summary​The US Department of Veterans Affairs (VA) has announced a new clinical trial to evaluate the effectiveness of semaglutide in treating AUD and is aimed directly at benefiting Veterans. ​Currently, more than 400,000 US veterans have been diagnosed with AUD, while an estimated 11% of US adults are affected by the condition.
Can GLP-1 Drugs Like Ozempic Treat Alcohol Use Disorder? US Launches Veterans Trial

Blockbuster GLP-1 drugs, with semaglutide as the key ingredient, have shown promise in treating conditions ranging from diabetes and obesity to certain cancers.

Now, US researchers are set to test whether semaglutide can also help treat alcohol use disorder (AUD), particularly among veterans. AUD affects an estimated 400 million people worldwide, or about 7% of people aged 15 years and older.

The US Department of Veterans Affairs (VA) has announced a new clinical trial to evaluate the effectiveness of semaglutide in treating AUD and is aimed directly at benefiting Veterans.

"By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery," said VA Secretary Doug Collins.

Currently, more than 400,000 US veterans have been diagnosed with AUD, while an estimated 11% of US adults are affected by the condition.

What Does the Trial Aim to Find?

Also read: GLP-1 Weight-Loss Drugs Show Promise for 17 Million With Binge Eating Disorder, Suggests Study

The study, called the Cessation or Reduction of Alcohol Consumption in Veterans (CRACV) trial, will enroll more than 600 veterans across 18 VA medical centers in the US.

Participants aged 18 to 80 with moderate or severe AUD will receive weekly injections of either semaglutide or a placebo for 24 weeks, followed by a safety follow-up period.

Researchers will assess changes in alcohol consumption, overall health, and quality of life to determine whether semaglutide could become a new treatment option for alcohol use disorder.

Oral Semaglutide May Help Reduce Heavy Drinking

Evidence is also emerging that GLP-1 medications may influence alcohol consumption. A Phase 2 clinical trial published in the American Journal of Psychiatry in July suggests that oral semaglutide may help reduce heavy and harmful drinking, even among people who are not trying to quit alcohol completely.

The trial included 50 adults with moderate to severe alcohol use disorder who wanted to reduce or stop drinking. Participants were randomly assigned to receive either daily oral semaglutide or a placebo for eight weeks.

The semaglutide dose increased from 3 mg per day during the first four weeks to 7 mg per day during the remaining four weeks.

Read More: GLP-1 Microdosing: People Are Experimenting With Weight Loss Drugs & What Do Experts Have To Say About It?

While semaglutide did not significantly reduce laboratory-assessed craving or the average number of drinks per day compared with placebo, it significantly reduced heavy drinking days.

Compared with participants receiving placebo, those taking semaglutide had fewer heavy drinking days during the final four weeks of treatment. They also consumed fewer drinks on drinking days and reported greater reductions in everyday alcohol cravings and alcohol-related negative consequences.

"It could represent a new treatment option for alcohol use disorder, particularly for those who have not benefited from existing medications, and may reduce alcohol-related health and social harms. Importantly, even reducing heavy drinking can lead to meaningful improvements for patients and families," said Joseph Schacht, PhD, professor of psychiatry at the University of Colorado Anschutz School of Medicine.

End of Article

Why Are More Women Under 35 Reporting Heart-Related Symptoms?

Updated Aug 3, 2026 | 02:00 PM IST

SummaryLack of physical activity, improper diet, obesity, diabetes, high blood pressure, smoking, and continuous stress have been labeled responsible for these problems. Some women's conditions like PCOD and autoimmune diseases can also put them at a higher cardiovascular risk.
Why Are More Women Under 35 Reporting Heart-Related Symptoms?

Credit: iStock

As many as 23 cases of young women aged below 35 suffering from heart-related problems in only a month (reported by the Indian Medical Association) have left cardiologists concerned. What were earlier considered symptoms of stress, anxiety, and hormonal imbalances such as chest pain, breathing difficulty, palpitations, unexplained fatigue, and giddiness are now not being taken lightly when they occur for a prolonged time or recur. They are being increasingly identified as cardiac-related problems even in young adults.

Lack of physical activity, improper diet, obesity, diabetes, high blood pressure, smoking, and continuous stress have been labeled responsible for these problems. Some women's conditions like PCOD and autoimmune diseases can also put them at a higher cardiovascular risk. Regular check-ups, monitoring of blood pressure, blood sugar, cholesterol levels, and timely check-ups for the heart whenever these conditions occur can help in detecting the problems at the earliest, thus initiating treatment and recovery effectively.

In today's times, management of complicated heart diseases in India has dramatically improved and achieved outcomes at par with global standards. Today, the management of very severe heart valve disease offers much in terms of percutaneous catheter-based solutions, which, alongside conventional surgery (performed according to a person's age, general health, and clinical profile), give improved outcomes. Early detection and management of heart diseases prevent major complications and restore an individual's quality of life.

Increased knowledge about heart health, early identification of symptoms, and immediate medical attention are very important to achieve successful results. The observance of preventive measures such as engaging in regular exercise, a healthy diet, sleep, managing stress, and conducting regular medical checkups helps in the prevention of heart problems. Early diagnosis and adequate treatment form the key factors for achieving the best heart health.

By Dr. Nagendra Singh Chouhan, Interventional Cardiologist at Medanta Hospitals, Gurugram

End of Article